A phase 2 trial tested the efficacy of local stereotactic body radiation therapy (SBRT) use after radical prostatectomy.

PAM50, a genomic biomarker test, can classify prostate cancers into subtypes luminal B and non-luminal B, predicting which ...

How do we know which patients truly need this difficult treatment and which patients can safely skip it? The answer has arrived, delivered at the American Society for Radiation Oncology (ASTRO) 2025 ...

A genetic test could guide the use of hormone therapy for men with recurrent prostate cancer after surgery, according to data ...

UCLA investigators found that stereotactic body radiotherapy (SBRT), a form of high-dose radiation delivered in just five sessions, after prostate surgery is safe and as effective as traditional, ...

Recurrent prostate cancer patients with luminal B tumors may benefit from hormone therapy added to radiation following surgery.

Imagine a future where the moment you’re born, a virtual avatar is created and steadily filled with personalised information ...

Despite SBRT (radiation) to oligometastatic sites, prostate cancer progression still occurs in a majority of patients due to occult microscopic disease.

Morrow is now devoting his life to prostate cancer advocacy and urging other younger, high-risk men to get screened early. He ...

Genitourinary cancers require individualized treatment plans based on type, stage, and patient health, utilizing imaging, ...

Discover a study on focal therapy for prostate cancer, showing how the Decipher genomic score predicts treatment success and ...